BRPI0606148A2 - anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus - Google Patents
anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrusInfo
- Publication number
- BRPI0606148A2 BRPI0606148A2 BRPI0606148-6A BRPI0606148A BRPI0606148A2 BR PI0606148 A2 BRPI0606148 A2 BR PI0606148A2 BR PI0606148 A BRPI0606148 A BR PI0606148A BR PI0606148 A2 BRPI0606148 A2 BR PI0606148A2
- Authority
- BR
- Brazil
- Prior art keywords
- sars
- cov
- acute respiratory
- respiratory syndrome
- coronavirus
- Prior art date
Links
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 title abstract 5
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 241000315672 SARS coronavirus Species 0.000 abstract 3
- 229940096437 Protein S Drugs 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 102000029301 Protein S Human genes 0.000 abstract 1
- 108010066124 Protein S Proteins 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940124452 immunizing agent Drugs 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 238000011221 initial treatment Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS MONOCLONAIS NEUTRALIZANTES CONTRA A SìNDROME RESPIRATóRIA AGUDA GRAVE ASSOCIADA COM O CORONAVìRUS. A presente invenção fornece um anticorpo isolado capaz de ligar-se ao domínio de ligação do receptor da proteína spike da síndrome respiratória aguda grave - associada com o coronavírus (SARS-CoV) de forma a inibir competitivamente a ligação da SARS-CoV para as células principais. Estes mAbs ou substâncias podem ser usadas: 1) como agents imunizantes passivos para a prevenção da infecção da SARS-CoV; 2) como reagentes biológicos para o diagnóstico da infecção da SARS-CoV; 3) como imunoterapêuticos para tratamento inicial da infecção da SARS-CoV; e 4) como provas para estudar a imunogenicidade, antigenicidade, estrutura, e função da proteína S da SARS-CoV.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65104605P | 2005-02-08 | 2005-02-08 | |
| US14192505A | 2005-05-31 | 2005-05-31 | |
| PCT/US2006/004599 WO2006086561A2 (en) | 2005-02-08 | 2006-02-08 | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606148A2 true BRPI0606148A2 (pt) | 2009-06-02 |
Family
ID=36793717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606148-6A BRPI0606148A2 (pt) | 2005-02-08 | 2006-02-08 | anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1855719A4 (pt) |
| JP (1) | JP2008529504A (pt) |
| AT (1) | ATE556717T1 (pt) |
| AU (1) | AU2006213775C1 (pt) |
| BR (1) | BRPI0606148A2 (pt) |
| CA (1) | CA2595780A1 (pt) |
| ES (1) | ES2384497T3 (pt) |
| MX (1) | MX2007009512A (pt) |
| NZ (1) | NZ560328A (pt) |
| WO (1) | WO2006086561A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015189422A1 (en) * | 2014-06-12 | 2015-12-17 | Universidade Do Porto - Reitoria | Vaccine for immunocompromised hosts |
| CN113292650B (zh) * | 2020-02-24 | 2022-08-12 | 中国科学院微生物研究所 | 新型冠状病毒的人源单克隆抗体及其应用 |
| CN113292649B (zh) * | 2020-02-24 | 2022-08-12 | 中国科学院微生物研究所 | 新型冠状病毒的人源单克隆抗体及其应用 |
| CN111560074B (zh) * | 2020-03-20 | 2021-07-09 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 |
| CN111983226A (zh) | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
| WO2021202893A1 (en) * | 2020-04-03 | 2021-10-07 | Nonigenex, Inc. | Detecting adaptive immunity to coronavirus |
| JP7174961B2 (ja) * | 2020-05-01 | 2022-11-18 | 花王株式会社 | 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット |
| CN111995675B (zh) * | 2020-05-15 | 2021-03-23 | 潍坊医学院 | 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用 |
| WO2021238910A1 (en) * | 2020-05-25 | 2021-12-02 | Guo Bingshi | Anti-coronavirus spike protein antibodies and uses thereof |
| CN112017782A (zh) * | 2020-06-01 | 2020-12-01 | 北京松果天目健康管理有限公司 | SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法 |
| JP2023531368A (ja) * | 2020-06-25 | 2023-07-24 | グリックニック インコーポレイテッド | Ａｃｅ２－ｆｃ融合タンパク質および使用方法 |
| CN113945714B (zh) * | 2020-07-16 | 2023-01-31 | 南京蓬勃生物科技有限公司 | 新型冠状病毒中和抗体类药物中和能力的检测方法 |
| CN112010984B (zh) * | 2020-08-04 | 2021-10-12 | 广州千扬生物医药技术有限公司 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗 |
| EP4206224A1 (en) | 2020-08-26 | 2023-07-05 | National University Corporation Kumamoto University | Human antibody or antigen-binding fragment thereof against coronavirus spike protein |
| CN114181301B (zh) * | 2020-09-14 | 2023-04-28 | 复旦大学 | 针对SARS-CoV-2的无ADE效应的中和抗体 |
| CN113156129B (zh) * | 2021-01-13 | 2022-04-05 | 广东菲鹏生物有限公司 | 中和抗体高敏检测方法及产品 |
| CN115427441B (zh) * | 2021-01-27 | 2023-09-05 | 保诺生物科技(江苏)有限公司 | 针对sars-cov-2的抗体 |
| CN115141271B (zh) * | 2021-01-31 | 2024-06-11 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体xy7及其应用 |
| CN114859042B (zh) * | 2021-02-03 | 2023-11-03 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
| EP4089112A1 (en) * | 2021-05-14 | 2022-11-16 | Ustav organicke chemie a biochemie AV CR, v.v.i. | Antibody binding to rbd of spike protein of sars-cov-2 and a method for quantifying protective antibodies against sars-cov-2 |
| WO2023148641A1 (en) * | 2022-02-02 | 2023-08-10 | Translational Health Science And Technology Institute | Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof |
-
2006
- 2006-02-08 JP JP2007554351A patent/JP2008529504A/ja active Pending
- 2006-02-08 BR BRPI0606148-6A patent/BRPI0606148A2/pt not_active Application Discontinuation
- 2006-02-08 AU AU2006213775A patent/AU2006213775C1/en not_active Ceased
- 2006-02-08 WO PCT/US2006/004599 patent/WO2006086561A2/en active Application Filing
- 2006-02-08 EP EP06720569A patent/EP1855719A4/en not_active Withdrawn
- 2006-02-08 AT AT10151641T patent/ATE556717T1/de active
- 2006-02-08 ES ES10151641T patent/ES2384497T3/es active Active
- 2006-02-08 CA CA002595780A patent/CA2595780A1/en not_active Abandoned
- 2006-02-08 NZ NZ560328A patent/NZ560328A/en not_active IP Right Cessation
- 2006-02-08 MX MX2007009512A patent/MX2007009512A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006213775B2 (en) | 2010-11-11 |
| AU2006213775C1 (en) | 2011-11-03 |
| CA2595780A1 (en) | 2006-08-17 |
| JP2008529504A (ja) | 2008-08-07 |
| AU2006213775A1 (en) | 2006-08-17 |
| MX2007009512A (es) | 2008-02-21 |
| ATE556717T1 (de) | 2012-05-15 |
| WO2006086561A3 (en) | 2009-04-23 |
| NZ560328A (en) | 2010-05-28 |
| EP1855719A4 (en) | 2009-11-04 |
| WO2006086561A2 (en) | 2006-08-17 |
| ES2384497T3 (es) | 2012-07-05 |
| EP1855719A2 (en) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0606148A2 (pt) | anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus | |
| EA200970469A1 (ru) | Антитела-агонисты рецептора trkb и их применение | |
| BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
| WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| PH12017501075A1 (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
| BRPI0819916A2 (pt) | Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno. | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| BR112012012160A2 (pt) | material e métodos para tratar ou prevenir doenças associadas ao her-3 | |
| WO2007033230A3 (en) | Anti-cd3 antibody formulations | |
| PE20090145A1 (es) | Moleculas de enlace de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| WO2008076915A3 (en) | Treatment of pigs with pcv2 antigen | |
| BRPI0412567A (pt) | anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo | |
| UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| EP2535353A8 (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
| UA107929C2 (en) | Antibodies against cxcr4 for the treatment of hiv infection | |
| WO2008112003A3 (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
| WO2007081896A3 (en) | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents | |
| WO2009154995A3 (en) | Interleukin 10 receptor (il-10r) antibodies and methods of use | |
| WO2008108830A8 (en) | Immunogenic and therapeutic compositions for streptococcus pyogenes | |
| WO2008049990A3 (fr) | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |